This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
btk
BTK
BTK (Bruton's tyrosine kinase) is the critical BCR signaling kinase activating PLCγ2-Ca²⁺ and NF-κB → B-cell survival; germline BTK loss causes X-linked agammaglobulinemia; ibrutinib (covalent BTK inhibitor) and zanubrutinib are approved for CLL, MCL, WM, and MZL.
Entry Metadata
| Field | Value |
|---|---|
| ID | btk |
| Name | BTK |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. · PubMed 23782158
- Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516. · PubMed 23782157